I 

116TH CONGRESS 

2D SESSION H. R. 7288 

To direct the Secretary of Health and Human Services and other Federal 

officials to compile into a searchable database information relating to 

Federal support for biomedical research and development related to 

COVID–19, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 22, 2020 

Mr. DOGGETT (for himself, Mr. ROONEY of Florida, Ms. SCHAKOWSKY, Ms. 

DELAURO, Mr. DEFAZIO, Mr. POCAN, and Ms. JAYAPAL) introduced the 

following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, Veterans’ 

Affairs, Science, Space, and Technology, the Judiciary, and Ways and 

Means, for a period to be subsequently determined by the Speaker, in 

each case for consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To direct the Secretary of Health and Human Services and 

other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development related to COVID– 

19, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 7288 IH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Taxpayer Research 

3 and Coronavirus Knowledge Act of 2020’’. 

4 SEC. 2. DATABASE. 

5 (a) IN GENERAL.—The Secretary of Health and 

6 Human Services, the Director of the National Institutes 

7 of Health, the Assistant Secretary for Preparedness and 

8 Response of the Department of Health and Human Serv9 ices, the Director of the Biomedical Advanced Research 

10 and Development Authority, the Secretary of Defense, the 

11 Secretary of Veterans Affairs, the Director of the National 

12 Institute of Allergy and Infectious Diseases, and such 

13 other Federal officials as the Secretary of Health and 

14 Human Services determines to be relevant, acting in co15 ordination, shall— 

16 (1) compile into a searchable database informa17 tion relating to Federal support (before or after the 

18 date of enactment of this Act) for biomedical re19 search and development related to COVID–19 (in20 cluding biomedical research and development relat21 ing to a product or therapy that was later modified 

22 or repurposed to be used for COVID–19); and 

23 (2) make such database available on the public 

24 website of the Department of Health and Human 

25 Services. 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 7288 IH

1 (b) COVERED INFORMATION.—The information relat2 ing to Federal support referred to in subsection (a)(1) in3 cludes all contracts, funding agreements, licensing ar4 rangements, other transactions, and other arrangements 

5 entered into by the Federal Government and tax benefits 

6 provided with respect to research and development, and 

7 manufacturing, of a drug (including biological products), 

8 cell or gene therapy, or medical device intended to be man9 ufactured, used, designed, developed, modified, 

10 repurposed, licensed, or procured to diagnose, mitigate, 

11 prevent, treat, or cure COVID–19, including but not lim12 ited to the following: 

13 (1) Licensing agreements pursuant to section 

14 207 of title 35, United States Code. 

15 (2) Cooperative research and development 

16 agreements and licensing agreements pursuant to 

17 section 3710a of title 15, United States Code. 

18 (3) Funding agreements, as defined under sec19 tion 201 of title 35, United States Code. 

20 (4) Other transactions entered into pursuant to 

21 the following statutes: 

22 (A) Section 319L of the Public Health 

23 Service Act (42 U.S.C. 247d–7e). 


kjohnson on DSK79L0C42PROD with BILLS
4 

•HR 7288 IH

1 (B) Section 105 of the National Institutes 

2 of Health Reform Act of 2006 (42 U.S.C. 

3 284n). 

4 (C) Section 480 of the Public Health Serv5 ice Act (42 U.S.C. 287a). 

6 (D) Section 421 of the Public Health Serv7 ice Act (42 U.S.C. 285b–3). 

8 (E) Section 2371 of title 10, United States 

9 Code. 

10 (5) Tax credits and deductions associated 

11 with— 

12 (A) qualified clinical testing expenses, as 

13 defined under section 45C of title 26, United 

14 States Code; 

15 (B) qualified research expenses, as defined 

16 under section 41 of title 26, United States 

17 Code; and 

18 (C) charitable contributions, as defined 

19 under section 170(c) of title 26, United States 

20 Code, to patient assistance programs. 

21 (c) INFORMATION REQUIRED.—Notwithstanding any 

22 other provision of law, the Federal officials referred to in 

23 subsection (a) shall include in the database under sub24 section (a), with regard to each contract, funding agree25 ment, licensing arrangement, other transaction, other arVerDate Sep 11 2014 00:29 Jul 11, 2020 Jkt 099200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H7288.IH H7288

kjohnson on DSK79L0C42PROD with BILLS
5 

•HR 7288 IH

1 rangement, or tax benefit described in subsection (b), at 

2 least the following information: 

3 (1) The agency, program, institute, or other 

4 Federal Government entity providing the Federal 

5 support. 

6 (2) The amount and period of Federal financial 

7 support with an itemized breakdown. 

8 (3) Other Federal nonfinancial support, includ9 ing but not limited to the use of Federal personnel, 

10 Federal facilities, and Federal equipment. 

11 (4) The grant number, if applicable. 

12 (5) Associated clinical trial data, upon trial 

13 completion. 

14 (6) Associated patents and patent applications, 

15 specifying— 

16 (A) any Federal ownership in such patents 

17 and patent applications; 

18 (B) the expiration date of such patents 

19 and filing dates of such patent applications; and 

20 (C) the numbers of such patents and pat21 ent applications. 

22 (7) Associated periods of marketing exclusivity 

23 under Federal law and the durations of such peri24 ods. 


kjohnson on DSK79L0C42PROD with BILLS
6 

•HR 7288 IH

1 (8) The corporation, nonprofit organization, 

2 academic institution, person, or other entity receiv3 ing the Federal support. 

4 (9) Any products (including repurposed prod5 ucts) approved, authorized, or cleared for marketing, 

6 or for which marketing approval, authorization, or 

7 clearance is being sought, the development of which 

8 was aided by Federal support, including— 

9 (A) the names of such products; 

10 (B) the prices of such products; and 

11 (C) the current and anticipated manufac12 turing capacity to produce such products. 

13 (10) The full terms of the contract, funding 

14 agreement, licensing arrangement, other transaction, 

15 or other arrangement described in subsection (b). 

16 (d) FORMAT OF INFORMATION.—The database under 

17 subsection (a) shall be— 

18 (1) searchable and filterable according to the 

19 categories of information described in subsection (c); 

20 and 

21 (2) presented in a user-friendly format. 

22 (e) TIMING.—The database under subsection (a) 

23 shall be— 

24 (1) made publicly available not later than 1 

25 month of the date of enactment of this Act; and 


kjohnson on DSK79L0C42PROD with BILLS
7 

•HR 7288 IH

1 (2) updated not less than every 2 weeks. 

2 (f) DISCLOSURE.— 

3 (1) IN GENERAL.—Notwithstanding any other 

4 provision of law, to the extent necessary for an offi5 cial referred to in subsection (a) to carry out this 

6 section, such official may require entities receiving 

7 Federal support referred to in subsection (a)(1) to 

8 disclose to the official any information relating to 

9 such Federal support and required to be included in 

10 the database under subsection (a). 

11 (2) PENALTY FOR NONDISCLOSURE.—If an en12 tity that is required to disclose information pursuant 

13 to paragraph (1) fails to disclose such information 

14 within a reasonable period of time or within two 

15 weeks of the official requesting such information, 

16 whichever is sooner, then such entity and all execu17 tive officers employed by such entity shall no longer 

18 be eligible for the receipt of Federal support in the 

19 form of a contract, funding agreement, licensing ar20 rangement, other transaction, or other arrangement. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS